System:You are an AI assistant. User will you give you a task. Your goal is to complete the task as faithfully as you can. While performing the task think step-by-step and justify your steps.

User: Below, you will be given a text on participation criteria from a clinical trial on cancer drugs, marked by ### Input: . Answer the following questions on the text: - What is the T-stage of the tumor? - What is the N-stage of the tumor? - What is the M-stage of the tumor? To help you, you will also receive background information on the TNM classification , marked by BACKGROUND: ''' 

BACKGROUND: '''TNM Classification: system for malignancy classification
- T: Tumor; size and invasion into adjacent tissues
 - T0: No detectable tumor
 - T1-T4: Increasing size and invasiveness
 - Tis: Carcinoma in situ
 - Tx: Tumor unassessable
- N: Nodes; regional lymph node involvement
 - N0: No regional nodal spread
 - N1-N3: Increasingly distal nodal spread
 - Nx: Lymph nodes unassessable
- M: Metastasis; distant metastases of primary tumor
 - M0: No distant metastasis
 - M1: Presence of distant metastasis
Specific T and N values depend on tumor type and involved structures''' NAME_1 explicitly and step-by-step, explaining exactly which information you use to answer the questions.

### Input:

Summary: 

- Tumor malignancy and TNM stages: No information found in the given text.
- Prior treatment received: 
  - Biologic therapy: allowed if at least 60 days since prior immunotherapy.
  - Chemotherapy: allowed if at least 60 days since prior cytotoxic chemotherapy.
  - Endocrine therapy: various rules apply.
  - Radiotherapy: allowed if more than 7 days since prior therapy. Prior external-beam radiotherapy without steroid requirement allowed
  - Prior debulking surgery allowed if at least 30 days since last surgery
  - Prior adjuvant therapy for resected, synchronous stage IV disease allowed
  - Study therapy not allowed for adjuvant therapy for completely resected late solitary site of disease metastasis or non-metastatic disease
  - No prior participation in this clinical study allowed
  - At least 60 days since other prior anticancer drugs allowed
  - Concurrent seizure medication allowed
- Histologically confirmed renal cell cancer with clear cell component
- Stage IV disease
- Metastatic or incompletely resected disease
- Underwent complete or partial nephrectomy more than 90 days ago with no unresected primary cancer
- No more than 2 adverse factors: Hemoglobin \< 10.0 g/dL, Corrected calcium \> ULN, Lactic dehydrogenase \> 1.5 times